Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study
Authors' conclusion
Dapagliflozin reduced total BF mass, abdominal VAT and SAT areas, and showed better glycaemic control than glimepiride. Being safe and well-tolerated, dapagliflozin appears to be a more favourable alternative to sulphonylureas as add-on therapy after metformin monotherapy failure in Korean patients with type 2 diabetes.
Study context
- Population
- Korean patients with T2D inadequately controlled (HbA1c ≥7.0% and <10.0%) on metformin monotherapy (≥1000 mg/day), 14 centres106 completed
- Participants
- 124 patients
- Comparison
- Dapagliflozin vs glimepiride as add-on to metformin
- Dapagliflozinn = 60
- Glimepiriden = 61reference
- Primary endpoint
- Body composition: total body fat mass, abdominal VAT and SAT areas (DXA and abdominal CT)
- Follow-up
- 52 weeks
Methodological details52-week, multicentre, parallel-group, open-label, Phase IV
- 52-week
- Multicentre
- Parallel-group
- Open-label
- Phase IV
Primary result
As reported in the abstract
Body composition
- Dapagliflozin
- difference −2.59 kg body fat (BF) mass
- Dapagliflozin
- difference −1.94 % BF%
- Dapagliflozin
- difference −17.55 cm² visceral adipose tissue (VAT) area
- Dapagliflozin
- difference −18.39 cm² subcutaneous adipose tissue (SAT) area
Further findings
| Outcome | Estimate |
|---|---|
| Glycaemic, anthropometric, BP and adiponectin outcomes · 52 weeksDapagliflozin vs Glimepiride · statistically significant | difference −0.46 % HbA1c |
| Glycaemic, anthropometric, BP and adiponectin outcomes · 52 weeksDapagliflozin vs Glimepiride · statistically significant | difference −18.25 mg/dl fasting blood glucose |
| Glycaemic, anthropometric, BP and adiponectin outcomes · 52 weeksDapagliflozin vs Glimepiride · statistically significant | difference −3.7 kg weight |
| Glycaemic, anthropometric, BP and adiponectin outcomes · 52 weeksDapagliflozin vs Glimepiride · statistically significant | difference −2.21 cm waist circumference |
| Glycaemic, anthropometric, BP and adiponectin outcomes · 52 weeksDapagliflozin vs Glimepiride · statistically significant | difference −1.37 kg/m² BMI |
| Glycaemic, anthropometric, BP and adiponectin outcomes · 52 weeksDapagliflozin vs Glimepiride · statistically significant | difference −6.81 mmHg systolic BP |
| Glycaemic, anthropometric, BP and adiponectin outcomes · 52 weeksDapagliflozin vs Glimepiride · statistically significant | difference +657.71 ng/ml adiponectin |
Safety
Adverse events and hypoglycaemia
- Hypoglycaemic events reported in the glimepiride group
- 12 of 15
- Similar incidences of adverse events in both groups
Original publication
Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study. Diabetes Obes Metab. Published 20 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →